Skip to main content
. 2010 May 18;21(6):739–749. doi: 10.1089/hum.2009.190

FIG. 1.

FIG. 1.

(A) Schematic of natural binding of FX to the adenovirus hexon. (B) Schematic of the engineered GLA–ScFv fusion protein strategy for generating targeting ligands. (C) GLA fusion protein constructs and controls designed for Her2, EGFR, and ABCG2 targeting. ABCG2, ATP-binding cassette protein G2; Ad5, adenovirus serotype 5; EGF, epidermal growth factor; EGFR, EGF receptor; GFP, green fluorescent protein; His6, hexahistidine; SA, streptavidin; ScFv, single-chain antibody variable fragment.